SG11201900028VA - Crispr/cas9-based compositions and methods for treating cancer - Google Patents

Crispr/cas9-based compositions and methods for treating cancer

Info

Publication number
SG11201900028VA
SG11201900028VA SG11201900028VA SG11201900028VA SG11201900028VA SG 11201900028V A SG11201900028V A SG 11201900028VA SG 11201900028V A SG11201900028V A SG 11201900028VA SG 11201900028V A SG11201900028V A SG 11201900028VA SG 11201900028V A SG11201900028V A SG 11201900028VA
Authority
SG
Singapore
Prior art keywords
crispr
methods
international
baltimore
cas9
Prior art date
Application number
SG11201900028VA
Other languages
English (en)
Inventor
Vinod Jaskula-Ranga
Donald Zack
Fred Bunz
Original Assignee
The Johnson Hopkins Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Johnson Hopkins Univ filed Critical The Johnson Hopkins Univ
Publication of SG11201900028VA publication Critical patent/SG11201900028VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/761Adenovirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14132Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
SG11201900028VA 2016-07-05 2017-07-05 Crispr/cas9-based compositions and methods for treating cancer SG11201900028VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662358339P 2016-07-05 2016-07-05
PCT/US2017/040696 WO2018009525A1 (en) 2016-07-05 2017-07-05 Crispr/cas9-based compositions and methods for treating cancer

Publications (1)

Publication Number Publication Date
SG11201900028VA true SG11201900028VA (en) 2019-01-30

Family

ID=60913122

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900028VA SG11201900028VA (en) 2016-07-05 2017-07-05 Crispr/cas9-based compositions and methods for treating cancer

Country Status (14)

Country Link
US (1) US20200069818A1 (pt)
EP (1) EP3481431A4 (pt)
JP (1) JP2019520394A (pt)
KR (1) KR20190039115A (pt)
CN (1) CN109963598A (pt)
AU (1) AU2017292772A1 (pt)
BR (1) BR112019000107A2 (pt)
CA (1) CA3029908A1 (pt)
CL (1) CL2019000023A1 (pt)
EA (1) EA201990214A1 (pt)
IL (1) IL264034A (pt)
MX (1) MX2019000188A (pt)
SG (1) SG11201900028VA (pt)
WO (1) WO2018009525A1 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6930834B2 (ja) * 2014-06-16 2021-09-01 ザ・ジョンズ・ホプキンス・ユニバーシティー H1プロモーターを用いるcrisprガイドrnaの発現のための組成物および方法
US9855445B2 (en) 2016-04-01 2018-01-02 Varian Medical Systems, Inc. Radiation therapy systems and methods for delivering doses to a target volume
US11590364B2 (en) 2017-07-21 2023-02-28 Varian Medical Systems International Ag Material inserts for radiation therapy
US10183179B1 (en) 2017-07-21 2019-01-22 Varian Medical Systems, Inc. Triggered treatment systems and methods
US10549117B2 (en) 2017-07-21 2020-02-04 Varian Medical Systems, Inc Geometric aspects of radiation therapy planning and treatment
US10843011B2 (en) 2017-07-21 2020-11-24 Varian Medical Systems, Inc. Particle beam gun control systems and methods
US11712579B2 (en) 2017-07-21 2023-08-01 Varian Medical Systems, Inc. Range compensators for radiation therapy
US10092774B1 (en) 2017-07-21 2018-10-09 Varian Medical Systems International, AG Dose aspects of radiation therapy planning and treatment
CN111556776B (zh) 2017-11-16 2022-09-02 瓦里安医疗系统公司 用于放射疗法系统的增加的束输出和动态场成形
CN108265116A (zh) * 2018-01-22 2018-07-10 上海市第人民医院 Klf4作为肝癌疾病诊断和治疗靶点
US20210054405A1 (en) * 2018-03-02 2021-02-25 Generation Bio Co. Closed-ended dna (cedna) vectors for insertion of transgenes at genomic safe harbors (gsh) in humans and murine genomes
JP2021518160A (ja) * 2018-03-15 2021-08-02 ケーエスキュー セラピューティクス, インコーポレイテッド 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
US11865164B2 (en) 2018-03-27 2024-01-09 G+Flas Life Sciences Pharmaceutical composition for treating cancer, containing guide RNA and endonuclease as active ingredients
EP3781196B1 (en) 2018-03-27 2024-03-06 G+Flas Life Sciences Sequence-specific in vivo cell targeting
US20210115449A1 (en) * 2018-04-19 2021-04-22 Board Of Regents, The University Of Texas System Therapeutic modulation of tumor suppressors using exosomes
CN108588194A (zh) * 2018-05-28 2018-09-28 北京诺禾致源科技股份有限公司 利用高通量测序数据检测肿瘤突变负荷的方法及装置
WO2020022802A1 (ko) * 2018-07-25 2020-01-30 주식회사 툴젠 인위적인 유전자 조작을 통한 자가면역질환 치료
US10910188B2 (en) 2018-07-25 2021-02-02 Varian Medical Systems, Inc. Radiation anode target systems and methods
CN112955550A (zh) * 2018-09-12 2021-06-11 基础科学研究院 诱导具有突变基因的细胞的死亡的组合物以及通过使用所述组合物诱导具有突变基因的细胞的死亡的方法
IT201800009431A1 (it) * 2018-10-15 2020-04-15 Universita' Degli Studi Di Siena Sistema CRISPR-Cas per l’editing genomico.
EP3640329A1 (en) * 2018-10-18 2020-04-22 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Gene editing based cancer treatment
US11116995B2 (en) 2019-03-06 2021-09-14 Varian Medical Systems, Inc. Radiation treatment planning based on dose rate
US10814144B2 (en) 2019-03-06 2020-10-27 Varian Medical Systems, Inc. Radiation treatment based on dose rate
US11090508B2 (en) 2019-03-08 2021-08-17 Varian Medical Systems Particle Therapy Gmbh & Co. Kg System and method for biological treatment planning and decision support
US11103727B2 (en) 2019-03-08 2021-08-31 Varian Medical Systems International Ag Model based PBS optimization for flash therapy treatment planning and oncology information system
CN109897854B (zh) * 2019-03-28 2020-12-25 江苏浦珠生物医药科技有限公司 一种双sgRNA位点敲除ZYG11A基因的CRISPR/Cas9系统与应用
JP2022533268A (ja) 2019-05-23 2022-07-21 クリスティアナ ケア ヘルス サービシズ,インコーポレーテッド がんを処置するためのバリアントnrf2の遺伝子ノックアウト
US10918886B2 (en) 2019-06-10 2021-02-16 Varian Medical Systems, Inc. Flash therapy treatment planning and oncology information system having dose rate prescription and dose rate mapping
WO2021050937A1 (en) * 2019-09-12 2021-03-18 The Wistar Institute Of Anatomy And Biology Methods for the treatment of arid1a-deficient cancers
US11291859B2 (en) 2019-10-03 2022-04-05 Varian Medical Systems, Inc. Radiation treatment planning for delivering high dose rates to spots in a target
CN110772646A (zh) * 2019-10-15 2020-02-11 天津大学 共载多烯紫杉醇与crispr/cas9脂质体及应用
KR102337860B1 (ko) * 2019-11-05 2021-12-10 중앙대학교 산학협력단 슈와크만-보디안-다이아몬드 증후군 유전자의 발현 억제제를 유효성분으로 포함하는 유방암 치료제 효율 증진용 조성물
KR20210116324A (ko) * 2020-03-12 2021-09-27 기초과학연구원 게놈 서열 변이를 가지는 세포 사멸 유도용 조성물 및 상기 조성물을 이용한 세포 사멸 유도 방법
US11865361B2 (en) 2020-04-03 2024-01-09 Varian Medical Systems, Inc. System and method for scanning pattern optimization for flash therapy treatment planning
WO2021216503A1 (en) * 2020-04-20 2021-10-28 Christiana Care Health Services, Inc. Aav delivery system for lung cancer treatment
CA3181170A1 (en) * 2020-04-24 2021-10-28 Aadigen, Llc Compositions for treating cancer with kras mutations and uses thereof
US11541252B2 (en) 2020-06-23 2023-01-03 Varian Medical Systems, Inc. Defining dose rate for pencil beam scanning
US11957934B2 (en) 2020-07-01 2024-04-16 Siemens Healthineers International Ag Methods and systems using modeling of crystalline materials for spot placement for radiation therapy
WO2023070108A1 (en) * 2021-10-22 2023-04-27 Spotlight Therapeutics Guide rnas and uses thereof
WO2023143474A1 (en) * 2022-01-26 2023-08-03 Anchordx Medical Co., Ltd. Methods for treating gastric cancer
WO2023205844A1 (en) * 2022-04-26 2023-11-02 Peter Maccallum Cancer Institute Nucleic acids and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2926021T3 (es) * 2012-10-23 2022-10-21 Toolgen Inc Composición para escindir un ADN objetivo que comprende un ARN guía específico para el ADN objetivo y ácido nucleico codificador de proteína Cas o proteína Cas, y uso de la misma
EP3011034B1 (en) * 2013-06-17 2019-08-07 The Broad Institute, Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
US20150098954A1 (en) * 2013-10-08 2015-04-09 Elwha Llc Compositions and Methods Related to CRISPR Targeting
JP6930834B2 (ja) * 2014-06-16 2021-09-01 ザ・ジョンズ・ホプキンス・ユニバーシティー H1プロモーターを用いるcrisprガイドrnaの発現のための組成物および方法
WO2016049024A2 (en) * 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo
WO2016054225A1 (en) * 2014-09-30 2016-04-07 Stc.Unm Plasmid delivery in the treatment of cancer and other disease states
EP3215168B1 (en) * 2014-10-31 2023-08-02 The Trustees of the University of Pennsylvania Altering gene expression in modified t cells and uses thereof

Also Published As

Publication number Publication date
MX2019000188A (es) 2019-06-20
US20200069818A1 (en) 2020-03-05
KR20190039115A (ko) 2019-04-10
CL2019000023A1 (es) 2019-06-21
BR112019000107A2 (pt) 2019-04-09
EP3481431A1 (en) 2019-05-15
AU2017292772A1 (en) 2019-02-21
WO2018009525A8 (en) 2019-02-07
WO2018009525A1 (en) 2018-01-11
CA3029908A1 (en) 2018-01-11
CN109963598A (zh) 2019-07-02
IL264034A (en) 2019-01-31
JP2019520394A (ja) 2019-07-18
EP3481431A4 (en) 2020-01-01
EA201990214A1 (ru) 2019-11-29

Similar Documents

Publication Publication Date Title
SG11201900028VA (en) Crispr/cas9-based compositions and methods for treating cancer
SG11201900049QA (en) Crispr/cas9-based compositions and methods for treating retinal degenerations
SG11201808990QA (en) Compositions for topical application of compounds
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201901126UA (en) Combination therapy for cancer
SG11201808125RA (en) Methods for solid tumor treatment
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201808682XA (en) Silicone atoms containing ivacaftor analogues
SG11201808913WA (en) Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer
SG11201900038QA (en) Compositions and methods comprising improvements of crispr guide rnas using the h1 promoter
SG11201803906PA (en) Control of cellular redox levels
SG11201806583XA (en) Compositions containing tucaresol or its analogs
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201909837YA (en) Methods for treating lung disorders
SG11201408605UA (en) Methods for biodegradable derivatization of cellulosic surfaces
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201903055UA (en) Inhibitors of glucocorticoid receptor
SG11201805771XA (en) Systems and methods for preparation of platelets
SG11201900361RA (en) Methods of treating prostate cancer
SG11201408509PA (en) Racecadotril lipid compositions
SG11201810940XA (en) Methods of treating pancreatic cancer
SG11201804220SA (en) Activated stem cells and systemic treatment methods for infected wounds
SG11201811482YA (en) Double targeted constructs to affect tumor kill
SG11201900123TA (en) Compositions and methods for treating frontotemporal dementia